Two months after receiving cetuximab, percentages of CD16+, CD56+, and CD16+CD56+ lymphocytes remained significantly decreased in the group of patients with metastatic colorectal cancer compared with those in the healthy individuals. Here, NCAM1 is linked to metastatic colorectal cancer.